Tacalyx Raises €14M from Extended Funding

Tacalyx, a biotech company that focuses on cancer, has expanded its initial fundraising phase to raise more than €14 million.

The reasoning behind Tacalyx is that antibodies against TACA can facilitate the targeted killing of cancerous cells and be utilised to create therapeutic agents such as T cell engagers (TCEs) or antibody-drug conjugates (ADCs).

The business’s chemical framework has been used to generate its anti-TACA antibodies. In order to facilitate the identification of novel TACAs, Tacalyx has also formed a number of university partnerships to broaden its research pipeline.

Tacalyx CEO Dr Peter Sondermann stated: “With these added funds, we will be able to make significant progress on two of our assets to the clinical candidate stage, and advance others so they are ready for preclinical development.”

Leading the additional funding investment was Thuja Capital, a recent Tacalyx backer. Evan Castiglia, a partner at Thuja Capital, will serve on Tacalyx’s board of directors as an aspect of the investment.